Drug Type Fusion protein |
Synonyms- |
Target |
Mechanism TGF-β1 inhibitors(Transforming growth factor beta 1 inhibitors), ULBP2 inhibitors(UL16 binding protein 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | PL | 26 Nov 2024 |